SG11201407688QA - Laquinimod formulations without alkalizing agent - Google Patents
Laquinimod formulations without alkalizing agentInfo
- Publication number
- SG11201407688QA SG11201407688QA SG11201407688QA SG11201407688QA SG11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA SG 11201407688Q A SG11201407688Q A SG 11201407688QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical composition
- subject
- stable pharmaceutical
- subject invention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 January 2014 (16.01.2014) WIPOIPCT (10) International Publication Number WO 2014/011750 A1 (51) International Patent Classification: A61K 31/47 ( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/049894 10 July 2013 (10.07.2013) English English (30) Priority Data: 61/670,268 11 July 2012 (11.07.2012) (71) Applicant (for BB only): TEVA PHARMACEUTICAL INDUSTRIES LTD. [LL/IL]; 5 Basel Street, P.O. Box 3190, 49131 Petach Tikva (IL). (71) Applicant (for all designated States except BB, US): TEVA PHARMACEUTICALS USA, INC. [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors; and (71) Applicants (for US only): SARFATII, Gadi [IL/IL] ; Kib butz Beit Guvrin (IL). LOVINGER, Ioana [IL/IL]; Rh. Tel Hai 98/3, 44245 Kfar Saba (IL). LICHT, Danit [IL/IL]; Rh. Keren Haysod 1, Givat Shmuel (IL). SAFADI, Muhammad [IL/IL]; c/o P.O. Box 50670, St. 5007 Apt. 5A, 16164 Nazareth (IL). (74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) © i> © T? i-H o CJ o & (54) Title: LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT (57) Abstract: The subject invention provides stable a pharmaceutical composition comprising therapeutically effective a amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition free of is an alkaliz - ing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical com - position and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with form of multiple a sclerosis or for alleviating a symptom of multiple sclerosis in subject a afflic ted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a sub - ject afflicted with form of multiple a sclerosis or for alleviating symptom a of multiple sclerosis in subject afflicted with form of a a multiple sclerosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 | |
| PCT/US2013/049894 WO2014011750A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407688QA true SG11201407688QA (en) | 2014-12-30 |
Family
ID=49914501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407688QA SG11201407688QA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
| SG10201700198VA SG10201700198VA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201700198VA SG10201700198VA (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (en) |
| EP (1) | EP2872141A4 (en) |
| JP (1) | JP2015527321A (en) |
| KR (1) | KR20150036553A (en) |
| CN (1) | CN104470519A (en) |
| AR (1) | AR091706A1 (en) |
| AU (1) | AU2013290274A1 (en) |
| BR (1) | BR112015000321A2 (en) |
| CA (1) | CA2873230A1 (en) |
| EA (1) | EA201590193A1 (en) |
| HK (1) | HK1209054A1 (en) |
| IL (1) | IL236229A0 (en) |
| MX (1) | MX2015000398A (en) |
| NZ (1) | NZ630241A (en) |
| SG (2) | SG11201407688QA (en) |
| TW (1) | TW201408299A (en) |
| UA (1) | UA115555C2 (en) |
| WO (1) | WO2014011750A1 (en) |
| ZA (1) | ZA201500287B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2234485T3 (en) | 2007-12-20 | 2014-06-30 | Teva Pharma | Stable laquinimod preparations |
| AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
| TW201400117A (en) | 2012-06-05 | 2014-01-01 | Teva Pharma | Treatment of ocular inflammatory disease using laquinimod |
| TW201410244A (en) | 2012-08-13 | 2014-03-16 | Teva Pharma | Laquinimod for treatment of GABA mediated disorders |
| JP2015535287A (en) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod amine salt |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| JP2017514824A (en) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with high disability |
| CN107823150A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | It is a kind of can rapid dispersion tablet and preparation method thereof |
| CN107823168A (en) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | A kind of rapidly-soluble tablet and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (en) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| CN101291911B (en) * | 2005-10-19 | 2014-08-13 | 泰华制药工业有限公司 | Crystals of laquinimod sodium, and process for the manufacture thereof |
| WO2007146248A2 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| PL2234485T3 (en) * | 2007-12-20 | 2014-06-30 | Teva Pharma | Stable laquinimod preparations |
| EP2376456A2 (en) * | 2008-12-17 | 2011-10-19 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| CA2843432A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/en unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en active Application Filing
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/en not_active Application Discontinuation
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/en unknown
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/en active Pending
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/en active Pending
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 EA EA201590193A patent/EA201590193A1/en unknown
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/en active Search and Examination
- 2013-10-07 UA UAA201413984A patent/UA115555C2/en unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
- 2015-10-08 HK HK15109818.4A patent/HK1209054A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL236229A0 (en) | 2015-01-29 |
| SG10201700198VA (en) | 2017-02-27 |
| US20140018386A1 (en) | 2014-01-16 |
| TW201408299A (en) | 2014-03-01 |
| EP2872141A4 (en) | 2016-01-13 |
| KR20150036553A (en) | 2015-04-07 |
| BR112015000321A2 (en) | 2017-06-27 |
| UA115555C2 (en) | 2017-11-27 |
| ZA201500287B (en) | 2016-10-26 |
| AR091706A1 (en) | 2015-02-25 |
| CN104470519A (en) | 2015-03-25 |
| MX2015000398A (en) | 2015-04-10 |
| HK1209054A1 (en) | 2016-03-24 |
| JP2015527321A (en) | 2015-09-17 |
| WO2014011750A8 (en) | 2014-12-04 |
| WO2014011750A1 (en) | 2014-01-16 |
| CA2873230A1 (en) | 2014-01-16 |
| EA201590193A1 (en) | 2015-04-30 |
| EP2872141A1 (en) | 2015-05-20 |
| NZ630241A (en) | 2017-09-29 |
| AU2013290274A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407688QA (en) | Laquinimod formulations without alkalizing agent | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| SG11201908977SA (en) | Niraparib formulations | |
| SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201406987UA (en) | Glucokinase activator compositions for the treatment of diabetes | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |